Glucagon-like Peptide-1 Prevents Beta Cell Glucolipotoxicity
Overview
Affiliations
Aims/hypothesis: We have provided evidence that glucagon-like peptide-1, a potential therapeutic agent in the treatment of diabetes, activates phosphatidylinositol-3 kinase/protein kinase B signalling in the pancreatic beta cell. Since this pathway promotes cell survival in a variety of systems, we tested whether glucagon-like peptide-1 protects beta cells against cell death induced by elevated glucose and/or non-esterified fatty acids.
Methods: Human islets and INS832/13 cells were cultured at glucose concentrations of 5 or 25 mmol/l in the presence or absence of palmitate. Apoptosis was evaluated by monitoring DNA fragmentation and chromatin condensation. Wild-type and protein kinase B mutants were overexpressed in INS832/13 cells using adenoviruses. Nuclear factor-kappa B DNA binding was assayed by electrophoretic mobility shift assay.
Results: In human pancreatic beta cells and INS832/13 cells, glucagon-like peptide-1 prevented beta cell apoptosis induced by elevated concentrations of (i) glucose (glucotoxicity), (ii) palmitate (lipotoxicity) and (iii) both glucose and palmitate (glucolipotoxicity). Overexpression of a dominant-negative protein kinase B suppressed the anti-apoptotic action of glucagon-like peptide-1 in INS832/13 cells, whereas a constitutively active protein kinase B prevented beta cell apoptosis induced by elevated glucose and palmitate. Glucagon-like peptide-1 enhanced nuclear factor-kappa B DNA binding activity and stimulated the expression of inhibitor of apoptosis protein-2 and Bcl-2, two anti-apoptotic genes under the control of nuclear factor-kappa B. Inhibition of nuclear factor-kappa B by BAY 11-7082 abolished the prevention of glucolipotoxicity by glucagon-like peptide-1.
Conclusions/interpretation: The results demonstrate a potent protective effect of glucagon-like peptide-1 on beta cell gluco-, lipo- and glucolipotoxicity. This effect is mediated via protein kinase B activation and possibly its downstream target nuclear factor-kappa B.
Gojani E, Wang B, Li D, Kovalchuk O, Kovalchuk I Int J Mol Sci. 2025; 26(1.
PMID: 39796271 PMC: 11720205. DOI: 10.3390/ijms26010421.
Merzeban D, El Amin Ali A, Hammad R, Elmahdi M, Sofi M, Mahmoud R J Mol Histol. 2024; 56(1):50.
PMID: 39704859 DOI: 10.1007/s10735-024-10326-x.
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management.
Holst J Nat Metab. 2024; 6(10):1866-1885.
PMID: 39160334 DOI: 10.1038/s42255-024-01113-9.
Heckmann N, Palmer R, Mayfield C, Gucev G, Lieberman J, Hong K Arthroplast Today. 2024; 27:101327.
PMID: 39071832 PMC: 11282421. DOI: 10.1016/j.artd.2024.101327.
Barakat G, Assi G, Khalil H, Khatib S Curr Diabetes Rev. 2024; 21(2):e160424228945.
PMID: 38629376 DOI: 10.2174/0115733998287178240403055901.